Kalbe Farma Announces Rp 250 Billion Share Buyback Initiative

Strategic Move to Stabilize Stock Price

PT Kalbe Farma Tbk (KLBF), a leading Indonesian pharmaceutical company, has announced plans for a significant share buyback program worth up to Rp 250 billion. The initiative is set to commence on December 16, 2025, and will continue until March 15, 2026, spanning a maximum period of three months as permitted by the Otoritas Jasa Keuangan (OJK).

Regulatory Compliance and Market Context

The buyback program is being executed in accordance with OJK regulations, specifically referencing Surat OJK No. S-102/D.04/2025 and POJK No. 13/2023 and POJK No. 29/2023. These regulations govern share repurchases during periods of significant market volatility, providing companies with a framework to undertake such actions while maintaining market stability.

Corporate Perspective and Market Implications

According to Kartika Setiabudy, Director of Kalbe Farma, the buyback program is a strategic move to demonstrate the company's confidence in its financial health and to potentially stabilize its stock price. This action is particularly noteworthy in the current market environment, where companies are looking for opportunities to enhance shareholder value and maintain investor confidence.

Financial and Market Analysis

The Rp 250 billion buyback represents a significant commitment by Kalbe Farma to its shareholders and the market. It not only underscores the company's robust financial position but also signals to investors that the management believes the current stock price is attractive. This move is likely to be viewed positively by the market, potentially leading to increased investor interest and support for the stock.